<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT201501128175N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2015-09-18</date_registration>
      <primary_sponsor>Endocrinology &amp; Metabolism Research Institute of Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Effect of Diabetes Education by Peer Coaching on Diabetes Control and Management</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Diabetes Education by Peer Coaching on Diabetes Control and Management</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2015-04-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>492</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/8620</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.</study_design>
      <phase>N/A</phase>
      <hc_freetext>type 2 Diabetes.</hc_freetext>
      <i_freetext>Intervention 1: An unblinded randomized clinical trial in which women with type 2 diabetes are divided into one of the two following categories:&#13;
•	intervention group: diabetic patients who received education through peer coaches.&#13;
Research  population is all women with type 2 diabetes who refer to the municipality clinics in Tehran and (Two clinics depend on endocrinology and metabolism research center and health centers in 22 districts of Tehran) for receiving primary care of diabetes (management and education).&#13;
Intervention: all patients according to the type of receiving drugs contacting with a peer for 6 months. Essential information will be obtained at the beginning of the project (pre-intervention) and 3, 6 and 12 months after intervention. Intervention will be continued for 6-month.&#13;
All patients in the intervention group, should have two telephone talks with peers, two times face to face meetings and receive three SMS (during one month). If essential they also receive two face-to-face. If necessary, they will have a clinic visit.&#13;
Meetings, phone talk or SMS, will be made based on the patient and  peer agreement.&#13;
All peers should be record every meeting or call history including contact time, contact type, contact duration, and the subject of talk.&#13;
Patients will be joint to the peers, according to the gender. &#13;
The first meeting takes place by telephone and introduction session between the peer and patient will be held.&#13;
Then specific clinical goals, including HbA1c, FBS, lipid profile (LDL, HDL, TG, Cholesterol) and high blood pressure, self-care skills such as using a glucometer and proper strategies during hypoglycemia, taking drugs, changing lifestyle, healthy eating, physical activity and stress will be discussed.&#13;
Peers and patients may have talked about family, job or hobbies on holidays. There is not any educational intervention between patient and peer at 6 month to 12 month of the intervention.&#13;
They just continue their relationship by telephone talking. at least all  information will be recorded and measured at 12 month. Intervention 2: An unblinded randomized clinical trial in which women with type 2 diabetes are divided into one of the two following categories:&#13;
&#13;
•	control group: diabetic patients who received routine care includes attending small group class on diabetes diabetes class or education through national media).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahnaz Sanjari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, North Karegar St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1411413137</zip>
        <telephone>+98 21 8822 0088</telephone>
        <email>emri-research@tums.ac.ir</email>
        <affiliation>Endocrinology and Metabolism Research Institute Tehran University of medical Sciences,Tehran, Iran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Neda Mehrdad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shariati Hospital, North Karegar St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8822 0088</telephone>
        <email>emri-research@tums.ac.ir</email>
        <affiliation>Endocrinology &amp; Metabolism Research Institute of Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria    &#13;
 Individuals eligible for attending in the study are women with type 2 diabetes who have HbA1c ≤ 8% in the last 6 months. Patients should not plan to migrate out of Tehran during the period of study and research team could easily have been in contact with them. Additionally, following criteria is essential:&#13;
•	Ability to speak in Persian &#13;
•	Age between 20 and 60 years old&#13;
•	To have HbA1c ≤ 8% in the last 6 months&#13;
•	Not be pregnant&#13;
•	Patients with a life expectancy of less than a year and has a serious illness and disease with reduced cognitive capacity approved by the health center staff will be recruited.&#13;
•	Patients who are currently enrolled in a diabetes education programs are not included in the study.&#13;
exclusion criteria    &#13;
•	To have HbA1c equal and above 9% during the study&#13;
•	Become pregnant during the study</inclusion_criteria>
      <agemin>73 years</agemin>
      <agemax>33 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Non-insulin-dependent diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>An unblinded randomized clinical trial in which women with type 2 diabetes are divided into one of the two following categories:&#13;
•	intervention group: diabetic patients who received education through peer coaches.&#13;
Research  population is all women with type 2 diabetes who refer to the municipality clinics in Tehran and (Two clinics depend on endocrinology and metabolism research center and health centers in 22 districts of Tehran) for receiving primary care of diabetes (management and education).&#13;
Intervention: all patients according to the type of receiving drugs contacting with a peer for 6 months. Essential information will be obtained at the beginning of the project (pre-intervention) and 3, 6 and 12 months after intervention. Intervention will be continued for 6-month.&#13;
All patients in the intervention group, should have two telephone talks with peers, two times face to face meetings and receive three SMS (during one month). If essential they also receive two face-to-face. If necessary, they will have a clinic visit.&#13;
Meetings, phone talk or SMS, will be made based on the patient and  peer agreement.&#13;
All peers should be record every meeting or call history including contact time, contact type, contact duration, and the subject of talk.&#13;
Patients will be joint to the peers, according to the gender. &#13;
The first meeting takes place by telephone and introduction session between the peer and patient will be held.&#13;
Then specific clinical goals, including HbA1c, FBS, lipid profile (LDL, HDL, TG, Cholesterol) and high blood pressure, self-care skills such as using a glucometer and proper strategies during hypoglycemia, taking drugs, changing lifestyle, healthy eating, physical activity and stress will be discussed.&#13;
Peers and patients may have talked about family, job or hobbies on holidays. There is not any educational intervention between patient and peer at 6 month to 12 month of the intervention.&#13;
They just continue their relationship by telephone talking. at least all  information will be recorded and measured at 12 month.</i_keyword>
      <i_keyword>An unblinded randomized clinical trial in which women with type 2 diabetes are divided into one of the two following categories:&#13;
&#13;
•	control group: diabetic patients who received routine care includes attending small group class on diabetes diabetes class or education through national media)</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>HbA1c. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: HPLC.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fasting Blood Suger. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Glocose Oxidase.</sec_outcome>
      <sec_outcome>Total Cholestrol. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: CHOD-Pap.</sec_outcome>
      <sec_outcome>Triglyseridi. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Gpo-pap.</sec_outcome>
      <sec_outcome>LDL. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: photometery.</sec_outcome>
      <sec_outcome>HDL. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: photometery.</sec_outcome>
      <sec_outcome>Body Mass Index. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: weight (kg) / height (m)2.</sec_outcome>
      <sec_outcome>Blood Pressure. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Manometer (mmhg).</sec_outcome>
      <sec_outcome>Waist to Hip Ratio. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: waist hip ratio measurement.</sec_outcome>
      <sec_outcome>Food intake. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: The three-day recall questionnaire.</sec_outcome>
      <sec_outcome>Levels of physical activity. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: International Physical Activity Questionnaire (IPAQ.</sec_outcome>
      <sec_outcome>Self-care activity. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: summery of diabetes self-care activities- SDSCA.</sec_outcome>
      <sec_outcome>Quality of Life. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Diabetes Quality of Life (DQOL) Questionnaire.</sec_outcome>
      <sec_outcome>Depression. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Beck Depression Inventory.</sec_outcome>
      <sec_outcome>Social Capital. Timepoint: Before the intervention and at 3, 6 and 12 months after intervention. Method of measurement: Social Capital Integrated questionaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Endocrinology &amp; Metabolism Research Institute of Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2014-12-28</approval_date>
        <contact_name>lEthics Committee of Endocrinology and Metabolism  Research Institute of  Tehran University of Medic</contact_name>
        <contact_address>Shariati Hospital, North Karegar St. Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
